Vaxart, Inc.
corporate_fare Company Profile
Vaxart, Inc. (OTC:VXRT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 42 items for VXRT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for VXRT spans 10-Q, 8-K, DEFA14A, DFAN14A.
Recent high-impact activity:
- Vaxart 10-Q: $65.5M Cash Lasts Into Q2 2027, Before Mid-2027 COVID Data
- Vaxart Q3 Revenue Falls to $10.6M; Cash Runway Into Q2 2027
- Vaxart Posts $72.4M in Q3 Revenue, a Massive Jump for the Micro-Cap
- Vaxart Shareholders Reject Say-on-Pay, Two Directors Barely Re-Elected Amid Proxy Fight
- Vaxart's Oral COVID-19 Vaccine Shows Positive 12-Month Safety in Phase 2b Sentinel Cohort
Financial Snapshot
Short Interest & Short Volume
3.95 days to coverFINRA reported short interest of 2,417,496 shares in VXRT as of the October 30, 2026 settlement, a 0.5% increase from the prior period — about 4.0 days to cover at its recent average daily volume. On November 20, 2026, 29.2% of VXRT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.